139 related articles for article (PubMed ID: 27842912)
1. Upregulation of SLC2 (GLUT) family genes is related to poor survival outcomes in papillary thyroid carcinoma: Analysis of data from The Cancer Genome Atlas.
Chai YJ; Yi JW; Oh SW; Kim YA; Yi KH; Kim JH; Lee KE
Surgery; 2017 Jan; 161(1):188-194. PubMed ID: 27842912
[TBL] [Abstract][Full Text] [Related]
2. mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.
Suh S; Kim YH; Goh TS; Jeong DC; Lee CS; Jang JY; Cha W; Han ME; Kim SJ; Kim IJ; Pak K
Yonsei Med J; 2018 Aug; 59(6):746-753. PubMed ID: 29978611
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
Wu MH; Shen WT; Gosnell J; Duh QY
Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma.
Shen L; Qian C; Cao H; Wang Z; Luo T; Liang C
World J Surg Oncol; 2018 Dec; 16(1):235. PubMed ID: 30558624
[TBL] [Abstract][Full Text] [Related]
5. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
[TBL] [Abstract][Full Text] [Related]
6. Recurrence-associated genes in papillary thyroid cancer: An analysis of data from The Cancer Genome Atlas.
Chien MN; Yang PS; Lee JJ; Wang TY; Hsu YC; Cheng SP
Surgery; 2017 Jun; 161(6):1642-1650. PubMed ID: 28237646
[TBL] [Abstract][Full Text] [Related]
7. Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.
Chai YJ; Yi JW; Jee HG; Kim YA; Kim JH; Xing M; Lee KE
PLoS One; 2016; 11(7):e0159235. PubMed ID: 27410688
[TBL] [Abstract][Full Text] [Related]
8. Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients?
Ebina A; Sugitani I; Fujimoto Y; Yamada K
Surgery; 2014 Dec; 156(6):1579-88; discussion 1588-9. PubMed ID: 25262223
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma: analysis of TCGA data.
Kim E; Jung S; Park WS; Lee JH; Shin R; Heo SC; Choe EK; Lee JH; Kim K; Chai YJ
BMC Cancer; 2019 Apr; 19(1):302. PubMed ID: 30943948
[TBL] [Abstract][Full Text] [Related]
10. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma.
Luo D; Chen H; Lu P; Li X; Long M; Peng X; Huang M; Huang K; Lin S; Tan L; Zhu Y; Chen Z; Ouyang N; Li H
Cancer Biomark; 2017; 18(3):273-284. PubMed ID: 28009325
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients.
Wang W; Su X; He K; Wang Y; Wang H; Wang H; Zhao Y; Zhao W; Zarnegar R; Fahey TJ; Teng X; Teng L
Cancer; 2016 Jan; 122(2):198-206. PubMed ID: 26506214
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of BRAF mutation in thyroid papillary cancer.
Fernandez IJ; Piccin O; Sciascia S; Cavicchi O; Repaci A; Vicennati V; Fiorentino M
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):919-25. PubMed ID: 23482475
[TBL] [Abstract][Full Text] [Related]
13. Preoperative subclinical hypothyroidism in patients with papillary thyroid carcinoma.
Ahn D; Sohn JH; Kim JH; Shin CM; Jeon JH; Park JY
Am J Otolaryngol; 2013; 34(4):312-9. PubMed ID: 23357595
[TBL] [Abstract][Full Text] [Related]
14. Prognostic indicators in well-differentiated thyroid carcinoma when controlling for stage and treatment.
Krook KA; Fedewa SA; Chen AY
Laryngoscope; 2015 Apr; 125(4):1021-7. PubMed ID: 25583017
[TBL] [Abstract][Full Text] [Related]
15. Routine central lymph node dissection with total thyroidectomy for papillary thyroid cancer potentially minimizes level VI recurrence.
Hall CM; Snyder SK; Maldonado YM; Lairmore TC
Surgery; 2016 Oct; 160(4):1049-1058. PubMed ID: 27521047
[TBL] [Abstract][Full Text] [Related]
16. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
[TBL] [Abstract][Full Text] [Related]
17. Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study.
Lee YC; Na SY; Park GC; Han JH; Kim SW; Eun YG
Surgery; 2017 Feb; 161(2):465-471. PubMed ID: 27574773
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.
Kim Y; Kim MH; Jeon S; Kim J; Kim C; Bae JS; Jung CK
PLoS One; 2017; 12(3):e0174737. PubMed ID: 28358874
[TBL] [Abstract][Full Text] [Related]
19. Implication of minimal extrathyroidal extension as a prognostic factor in papillary thyroid carcinoma.
Shin JH; Ha TK; Park HK; Ahn MS; Kim KH; Bae KB; Kim TH; Choi CS; Kim TK; Bae SK; Kim SH
Int J Surg; 2013; 11(9):944-7. PubMed ID: 23820062
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma.
Henke LE; Pfeifer JD; Ma C; Perkins SM; DeWees T; El-Mofty S; Moley JF; Nussenbaum B; Haughey BH; Baranski TJ; Schwarz JK; Grigsby PW
Cancer Med; 2015 Jun; 4(6):791-9. PubMed ID: 25712893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
